Lytix Biopharma today announces that the poster “LTX-315, an oncolytic peptide converts immunogenically 'cold' tumors to 'hot' in a majority of patients with advanced or metastatic tumours: results from an ongoing phase I study” will be presented at the American Society of Clinical Oncology Annual Meeting 2017 (ASCO). The poster includes safety, efficacy and immune data on 28 patients treated with LTX-315 monotherapy in advanced/metastatic tumours.

Poster Session: Developmental therapeutics-immunotherapy, June 5^th 8-11.30AM EST.
Abstract number: 3085
The abstract can be found on: http://abstracts.asco.org/199/AbstView_199_192334.html